Capgras Syndrome After Use of Synthetic Cannabinoids: an Adolescent Case

Türkiye'de "bonzai", "jamaika" olarak anılan sentetik kannabinoidlerin sık rastlanan psikoaktif etkileri arasında anksiyete, ajitasyon, irritabilite, konfüzyon, varsanılar ve sanrılar sayılmakta, sentetik kannabinoid kullanımıyla tetiklenen psikotik tablolara ilişkin olgulara giderek daha fazla bildirilmektedir. Capgras sendromu hastanın özgün kişi ve nesnelerin benzerleriyle yer değiştirildiğine inanmasıyla karakterize psikotik bir tablodur ve nadiren saf bir şekilde ortaya çıktığı, genelde şizofreni ya da organik psikozla birlikte görüldüğü belirtilmektedir. Burada sentetik kannabinoid kullanımı sonrasında gelişen Capgras sendromuyla başvuran bir ergen olgu sunularak sentetik kannabinoid kullanımı sonrasında gelişebilecek psikotik belirtilere ve nadir rastlanan bu psikotik tabloya dikkat çekmek amaçlanmıştır. Ailesi tarafından psikiyatri acil servisine getirilen ve yaklaşık 10 gündür hemen her gün "bonzai" kullandığı belirtilen 17 yaşında erkek hastada anne babasının değiştiği, yerlerine başkalarının geçtiği sanrısıyla belirli Capgras sendromu saptanmıştır. Psikotik belirtilerle başvuran ergenlerde laboratuar testleri negatif olsa dahi, sentetik kannabinoid kullanımı olasılığının göz önünde bulundurulması ve detaylı öykü alınması gerekmektedir. Hassas bir popülasyon olan ergenlerin ve onları yönlendirecek olan aile, okul gibi kurumların, "bitkisel", "doğal", "yasal" gibi söylemlerle pazarlanan ve kolaylıkla ulaşılabilir olan sentetik kannabinoidlerin olumsuz etkileri konusunda bilgilendirmesi, bu maddelerle tetiklenecek olan psikotik tabloların da önünde geçilmesinde yarar sağlayacaktır.

Sentetik kannabinoid kullanımı sonrası gelişen capgras sendromu: Bir ergen olgu

Anxiety, agitation, irritability, confusion, hallucinations and delusions are among common psychoactive effects of synthetic cannabinoids, which are referred as "bonsai" and "jamaica" in Turkey. Cases of psychotic disorder induced by synthetic cannabinoid use are becoming increasingly more reported. Capgras syndrome is a psychotic disorder characterized by a delusion that a specific person or object has been replaced by an identical one. It has been reported to occur rarely in pure form, but generally accompanying schizophrenia or organic psychosis. Herein we aim to report an adolescent case presenting with Capgras syndrome developed after use of synthetic cannabinoids and to draw attention to psychotic symptoms and to this uncommon psychotic syndrome which may occur after synthetic cannabinoid use. Seventeen years old male, who reported using "bonzai" for about 10 days, was brought to the emergency room by his family. Capgras syndrome, defined with delusion that his mother and father have been changed and replaced by others, has been detected. In adolescents who admit with psychotic symptoms, synthetic cannabinoid use should be considered and detailed history should be taken, even laboratory tests were negative. Adolescents, as a vulnerable population, should be informed about negative effects of synthetic cannabinoids which are easily accessible and distributed as "herbal", "natural" and "legal", as well as their parents and institutions such as schools which may guide them. Thus, it might be possible to prevent psychotic disorders which will be induced by this substances.

___

  • Evren C, Bozkurt M. Synthetic cannabinoids: crisis of the decade. Dusunen Adam: Journal of Psychiatry and Neurological Sciences 2013; 26:1-11. [CrossRef]
  • Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108:534-544. [CrossRef]
  • Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012; 21:320- 326. [CrossRef]
  • Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an exploratory study. Drug Alcohol Depend 2011; 117:152-157. [CrossRef]
  • Bozkurt M, Umut G, Evren C, Karabulut V. Clinical characteristics and laboratory test results of patients admitted to outpatient clinic for synthetic cannabinoid usage. Dusunen Adam: Journal of Psychiatry and Neurological Sciences 2014; 27:328-334. [CrossRef]
  • Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012; 129:1064-1067. [CrossRef]
  • Auwarter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44:832-837. [CrossRef]
  • Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:234-243. [CrossRef]
  • Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012; 120:238-241. [CrossRef]
  • Kucuk E, Kucuk I, Kirazaldi YY. A new threat in the emergency department: Synthetic cannabinoids (Bonzai, Jameika). Genel Tip Dergisi 2015; 25:18-22. (Turkish)
  • Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012; 60:435-438. [CrossRef]
  • Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: What the evidence says. Curr Psychiatr 2011; 10:49-58.
  • Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:319-328. [CrossRef]
  • Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev 2010; 29:304-317. [CrossRef]
  • Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011; 168:1119. [CrossRef]
  • Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict 2012; 21:287-288. [CrossRef]
  • Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 2012; 22:393-395. [CrossRef]
  • Sonmez I, Kosger F. Synthetic cannabinoid receptor agonist- associated psychotic disorder: a case report. Turk Psikiyatri Derg 2016; 27:63-66. (Turkish)
  • Hocaoglu C. Paranoid symptoms and syndromes. Psikiyatri Dunyasi 2001; 5:97-104. (Turkish)
  • Ozten E, Tufan AE, Yalug I, Cerit C, Isik S. Delusional incorrect recognition: a case presentation with Capgras syndrome. Klinik Psikiyatri Dergisi 2006; 9:45-48. (Turkish)
  • Castellanos D, Singh S, Thornton G, Avila M, Moreno A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011; 49:347-349. [CrossRef]
  • Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44:360-366. [CrossRef]
  • Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118:309-310. [CrossRef]
  • Van Der Veer N, Friday J. Persistent psychosis following the use of Spice. Schizophr Res 2011; 130:285-286. [CrossRef]
  • Benford DM, Caplan JP. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011; 52:295. [CrossRef]